#China #Shanghai #Allink Biotherapeutics #Lanchi Ventures #Gaorong Ventures

Allink Biotherapeutics Raises $42M in Series A Funding

Allink Biotherapeutics, a dynamic player in the biotechnology field, has announced its successful completion of a $42 million Series A financing round aimed at accelerating the development of its bispecific antibodies and antibody-drug conjugates (ADCs). This significant funding was led by Lanchi Ventures, a prominent early-stage technology investor, alongside contributions from a select group of investors, including Yuanbio Venture Capital, Legend Capital, and CD Emerging Industry Equity Investment, along with ongoing support from existing backers such as Gaorong Ventures and Med-Fine Capital.

Since its establishment just over a year ago, Allink Biotherapeutics has swiftly progressed from developing its lead assets to actively engaging in clinical development. Dr. Hui Feng, the founder and CEO of Allink Bio, expressed gratitude for the ongoing support and emphasized the company's commitment to transforming scientific innovations into clinical solutions. He stated, "We are poised to enhance our pipeline that addresses significant unmet medical needs across oncology and immunology. This funding enables us to amplify our efforts effectively."

The Impact of Series A Financing

The financing will be instrumental in facilitating the global Phase I and II clinical trials of Allink's lead candidates, namely ALK201 and ALK202, across various locations including the United States, China, and Australia. In addition, these funds will allow the company to diversify its asset portfolio by incorporating new highly competitive products focusing on oncology and immunology.

Lanchi Ventures highlighted that Allink's rapid advancement into clinical stages, under the leadership of Dr. Feng—a key figure in China's biopharmaceutical sector—demonstrates the company's competitive edge in the industry. The innovative strategy adopted by Allink in developing ADCs presents a compelling opportunity in targeted therapeutic areas.

Jiangtao Yu of Gaorong Ventures reiterated the confidence in Allink’s capabilities, remarking on the fast progress seen in both the company’s technology platforms and its pipeline. The firm anticipates participating actively in Allink's journey toward bringing groundbreaking therapies to market.

Future Prospects

With the secured funding, Allink plans to not only advance its clinical candidates but also to expand its proprietary bispecific antibody and ADC technology platforms. There is a strategic intent to broaden its global presence, enhancing its stature within the biopharmaceutical industry.

Dr. Feng's team has already demonstrated impressive execution by transitioning two ADC candidates into clinical trials within just 18 months of the company's inception. This efficiency reflects the team’s dedication and serves as a strong indicator of the company's promising future.

Notable Investors and Their Insight

Investors from various ventures, including Yuanbio Venture Capital and Med-Fine Capital, have expressed optimism surrounding Allink's trajectory. Med-Fine’s partner, Vince Deng, spoke highly of Dr. Feng's leadership and the potential impact that Allink's innovative therapies could have on global health.

About Allink Biotherapeutics

Founded in 2023, Allink Biotherapeutics specializes in developing First-in-Class (FIC) and Best-in-Class (BIC) therapeutics aimed at treating serious conditions in oncology and immunology. The company is dedicated to addressing critical global health needs through its innovative research and development methodologies.

Conclusion

As Allink continues to make strides in the biotechnology industry, this significant capital injection marks an exciting phase in its mission to deliver novel therapeutic solutions. With strong backing from esteemed investors and a commitment to advancing healthcare, Allink Biotherapeutics is poised to make a meaningful impact in the fight against serious diseases.